Supreme Court Orders Review of Pharmaceutical Marketing Practices: What’s Next?

Supreme Court's Directive on Pharmaceutical Regulations

New Delhi: On Thursday, the Supreme Court instructed the central government to form a committee tasked with evaluating the necessity for statutory oversight of marketing practices employed by pharmaceutical companies. This includes scrutinizing the provision of gifts, hospitality, and other incentives to healthcare professionals to promote their products.

The directive came from a Bench led by Justices Vikram Nath and Sandeep Mehta, during the hearing of a petition advocating for the regulation of pharmaceutical marketing and measures to mitigate unethical interactions between drug manufacturers and medical practitioners.

Solicitor General Tushar Mehta informed the Bench that a three-member committee would be established to assess whether a legal framework is needed to regulate pharmaceutical companies and, if so, to propose the structure of such regulations.

The government noted that while there are existing regulations that penalize doctors accepting benefits from pharmaceutical firms, the proposed committee will specifically address the need for regulations governing the companies themselves.

This committee will gather feedback from various stakeholders and provide recommendations to the government regarding the potential need for statutory regulations in pharmaceutical marketing.

Concerns were raised about the practice of pharmaceutical companies providing incentives such as gifts and travel to doctors to encourage them to prescribe their products.

The petitioners argued that the current regulatory framework creates an imbalance, holding doctors accountable for accepting inducements while lacking a corresponding mechanism to regulate or penalize the pharmaceutical companies offering them.

The Supreme Court has requested the Centre to submit an affidavit confirming compliance with its directives, with the case scheduled for further discussion on January 29.

This issue of pharmaceutical marketing practices is part of a broader examination by the Supreme Court regarding medicine pricing and accessibility.

In a separate series of public interest litigations concerning the regulation of drug prices, generic medications, and medical devices, the same Bench raised concerns about the significant price differences between what retailers pay for medicines and their maximum retail prices (MRP).

In a prior session, the Supreme Court questioned the government about a cancer medication priced at Rs 27,000, which was available to retailers for approximately Rs 2,700 to Rs 3,000.

The court characterized this ten-fold price discrepancy as 'broad daylight dacoity' and challenged the rationale behind allowing manufacturers to set MRPs significantly higher than the prices at which drugs are sold to retailers.

The Justice Nath-led Bench also inquired whether a uniform profit margin could be established for pharmaceutical products under the Essential Commodities Act, regardless of their classification as essential or non-essential under the Drug Price Control Order.

The Supreme Court highlighted that a substantial gap between MRP and retail prices could undermine consumer trust, suggesting that patients might suspect a medication to be counterfeit if a drug priced at Rs 27,000 is offered for around Rs 3,000.